EnteroMedics Inc. (NASDAQ:ETRM) belonging to the Medical sector has surged 89.95% and closed its last trading session at $3.97.
The company reported its EPS on 11/10/2016. Currently, the stock has a 1 Year Price Target of $140.
The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2 respectively.
EnteroMedics Inc. on 11/10/2016 reported its EPS as $-11.9 with the analysts projecting the EPS of the stock as $-34.65. The company beat the analyst EPS Estimate with the difference of $22.75. This shows a surprise factor of 65.7%.
Many analysts have provided their estimated foresights on EnteroMedics Inc. Earnings, with 1 analysts believing the company would generate an Average Estimate of $-35. Whereas they predicted High and Low Earnings Estimate as $-35 and $-35 respectively. While in the same Quarter Previous year, the Actual EPS was $-66.5.
Analysts are also projecting an Average Revenue Estimate for EnteroMedics Inc. as $300 Million in the Current Quarter. This estimate is provided by 1 analysts. The High Revenue estimate is predicted as 300 Million, while the Low Revenue Estimate prediction stands at 300 Million. The company’s last year sales total was 149 Million.
The Company got Downgrade by ROTH Capital on 9-Jun-16 from Buy to Neutral.
Insider Trades for EnteroMedics Inc. show that the latest trade was made on 2 Jun 2016 where Delange (Peter M), the Officer completed a transaction type “Buy” in which 20000 shares were traded at a price of $0.55.
1 analysts projected Price Targets for EnteroMedics Inc.. The analysts believe that the company stock price could grow as high as $140. The Low Price target projection by analysts is $140 and the Mean Price Target is $140.
EnteroMedics Inc. (NASDAQ:ETRM) has the market capitalization of $11.51 Million. The company rocked its 52-Week High of $4.98 on Jan 5, 2017 and touched its 52-Week Low of $0.04 on Dec 27, 2016. The stock has Return on Assets (ROA) of 0 percent. Return on Equity (ROE) stands at 0% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of 98.5 Percent. The company has Beta Value of 2.09 and ATR value of 0.44. The Weekly and Monthly Volatility stands at 37.82% and 25.36%.
EnteroMedics Inc. was established to develop and commercialize a new therapeutic platform for treating a wide range of acute and chronic diseases that are mediated by the vagal nerves. Due to the large unmet need for more effective surgical management of obesity, and following an in-depth analysis of how the vagus nerve affects food intake and processing, EnteroMedics has selected obesity management as its primary focus.